Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

The Drosophila FET orthologue Cabeza is an essential cofactor for ETV4-mediated activation of GGAA microsatellite neoenhancers

Created on 11 Jul 2026

Authors

Molnar, C., Reina, J., Mora, J., Gonzalez, C.

Abstract

The conversion of transcriptionally silent GGAA microsatellites (GGAASats) into functional enhancers by FET::ETS oncogenic fusions is a hallmark of Ewing sarcoma. However, emerging evidence implicates non-fused, full-length oncogenic ETS transcription factors in activating these repeats in other malignancies. Evaluating the in vivo transcriptional requirements of various human ETS factors in Drosophila, we found that human ETV4 uniquely binds and robustly activates GGAASats in a tissue-specific manner. This activation is strongly inhibited by the human ETS repressor ETV6. Taking advantage of low genetic redundancy in Drosophila, we identified Cabeza (Caz), the single fly FET orthologue, as a necessary cofactor for ETV4-mediated transcription at GGAASats. Conversely, EWS::FLI1-mediated transcriptional activation of GGAASats is entirely independent of endogenous Caz, highlighting the distinct mechanics of covalent tethering versus non-covalent physical complexes. Collectively, our findings provide definitive in vivo evidence that non-fused ETS factors cooperate with endogenous FET proteins to drive transcription from silent GGAA repeats, mechanistically validating this regulatory transformation known to operate as an oncogenic mechanism beyond Ewing sarcoma.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 11 Jul 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement